|
1
|
D'Addario G, Früh M, Reck M, Baumann P,
Klepetko W and Felip E; ESMO Guidelines Working Group, . Metastatic
non-small-cell lung cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 21 Suppl
5:v116–v119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sherwood JL, Corcoran C, Brown H, Sharpe
AD, Musilova M and Kohlmann A: Optimised pre-analytical methods
improve KRAS mutation detection in circulating tumour DNA (ctDNA)
from patients with non-small cell lung cancer (NSCLC). PLoS One.
11:e01501972016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quéré G, Descourt R, Robinet G, Autret S,
Raguenes O, Fercot B, Alemany P, Uguen A, Férec C, Quintin-Roué I
and Le Gac G: Mutational status of synchronous and metachronous
tumor samples in patients with metastatic non-small-cell lung
cancer. BMC Cancer. 16:2102016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zequn N, Xuemei Z, Wei L, Zongjuan M,
Yujie Z, Yanli H, Yuping Z, Xia M, Wei W, Wenjing D, et al: The
role and potential mechanisms of LncRNA-TATDN1 on metastasis and
invasion of non-small cell lung cancer. Oncotarget. 7:18219–18228.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Donáth J, Speer G, Kósa JP, Árvai K, Balla
B, Juhász P, Lakatos P and Poór G: Polymorphisms of CSF1 and TM7SF4
genes in a case of mild juvenile Paget's disease found using
next-generation sequencing. Croat Med J. 56:145–151. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chung PY, Beyens G, de Freitas F, Boonen
S, Geusens P, Vanhoenacker F, Verbruggen L, Van Offel J, Goemaere
S, Zmierczak HG, et al: Indications for a genetic association of a
VCP polymorphism with the pathogenesis of sporadic Paget's disease
of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms. Mol
Genet Metab. 103:287–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Valerio MS, Herbert BA, Griffin AC III,
Wan Z, Hill EG and Kirkwood KL: MKP-1 signaling events are required
for early osteoclastogenesis in lineage defined progenitor
populations by disrupting RANKL-induced NFATc1 nuclear
translocation. Bone. 60:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Safdari Y, Khalili M, Ebrahimzadeh MA,
Yazdani Y and Farajnia S: Natural inhibitors of PI3K/AKT signaling
in breast cancer: Emphasis on newly-discovered molecular mechanisms
of action. Pharmacol Res. 93:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye Y, Tang X, Sun Z and Chen S:
Upregulated WDR26 serves as a scaffold to coordinate PI3K/AKT
pathway-driven breast cancer cell growth, migration, and invasion.
Oncotarget. 7:17854–17869. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McAuliffe PF, Meric-Bernstam F, Mills GB
and Gonzalez-Angulo AM: Deciphering the Role of PI3K/Akt/mTOR
pathway in breast cancer biology and pathogenesis. Clin Breast
Cancer. 10 Suppl 3:S59–S65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu J, Lv H, Guan H, Ma X, Ji M, He N, Shi
B and Hou P: Metallothionein 1G functions as a tumor suppressor in
thyroid cancer through modulating the PI3K/Akt signaling pathway.
BMC Cancer. 13:4622013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung
cancer. Biochemical Pharmacol. 90:197–207. 2014. View Article : Google Scholar
|
|
14
|
Lu L, Li C, Li D, Wang Y, Zhou C, Shao W,
Peng J, You Y, Zhang X and Shen X: Cryptotanshinone inhibits human
glioma cell proliferation by suppressing STAT3 signaling. Mol Cell
Biochem. 381:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nam KS, Oh S, Lee KM, Yoo SA and Shin I:
CD44 regulates cell proliferation, migration, and invasion via
modulation of c-Src transcription in human breast cancer cells.
Cell Signal. 27:1882–1894. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Imogen L and Gillham CM: Chemotherapy for
lung cancer. N Engl J Med. 346:14982002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shaw AT, Ou SH, Bang YJ, Camidge DR,
Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa
DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung
cancer. N Engl J Med. 372:1963–1971. 2014. View Article : Google Scholar
|
|
19
|
Chung PY, Beyens G, Boonen S, Papapoulos
S, Geusens P, Karperien M, Vanhoenacker F, Verbruggen L, Fransen E,
Van Offel J, et al: The majority of the genetic risk for Paget's
disease of bone is explained by genetic variants close to the CSF1,
OPTN, TM7SF4, and TNFRSF11A genes. Hum Genet. 128:615–626. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Albagha OM, Wani S and Ralston SH:
Identification of a functional variant in the TM7SF4 gene that is
associated with susceptibility to Paget's disease of bone. Bone.
48:S882011. View Article : Google Scholar
|
|
21
|
Mino-Kenudson M and Mark EJ: Reflex
testing for epidermal growth factor receptor mutation and
anaplastic lymphoma kinase fluorescence in situ hybridization in
non-small cell lung cancer. Arch Pathol Lab Med. 135:655–664.
2011.PubMed/NCBI
|
|
22
|
Feng N, Luo J and Guo X: Silybin
suppresses cell proliferation and induces apoptosis of multiple
myeloma cells via the PI3K/Akt/mTOR signaling pathway. Mol Med Rep.
13:3243–3248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang G, Wang C, Sun M, Li J, Wang B, Jin
C, Hua P, Song G, Zhang Y, Nguyen LL, et al: Cinobufagin inhibits
tumor growth by inducing intrinsic apoptosis through AKT signaling
pathway in human nonsmall cell lung cancer cells. Oncotarget.
7:28935–28946. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao XZ, Liu Y, Zhou LJ, Wang ZQ, Wu ZH
and Yang XY: Role of estrogen in lung cancer based on the estrogen
receptor-epithelial mesenchymal transduction signaling pathways.
Onco Targets Ther. 8:2849–2863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Q, Liang X, Dai J and Guan X:
Prostaglandin transporter, SLCO2A1, mediates the invasion and
apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway. Int J
Clin Exp Pathol. 8:9175–9181. 2015.PubMed/NCBI
|
|
26
|
Hu J, Boeri M, Sozzi G, Liu D, Marchianò
A, Roz L, Pelosi G, Gatter K, Pastorino U and Pezzella F: Gene
signatures stratify computed tomography screening detected lung
cancer in high-risk populations. Ebiomedicine. 2:829–840. 2015.
View Article : Google Scholar
|
|
27
|
Wan J, Wu W, Chen Y, Kang N and Zhang R:
Insufficient radiofrequency ablation promotes the growth of
non-small cell lung cancer cells through PI3K/Akt/HIF-1α signals.
Acta Biochim Biophys Sin (Shanghai). 48:371–377. 2016. View Article : Google Scholar : PubMed/NCBI
|
